That’s why it’s our promise to make it accessible and affordable
through insurance and financial assistance
Insurers who have
coverage for hereditary
Patients who have $0
for testing at Myriad1
Patients have or will
qualify for a payment of
$100 or less1
Because BRACAnalysis CDx® is FDA-approved to identify patients who are or may become eligible for treatment with appropriate targeted therapies, Medicare will cover the testing for appropriate patients with ovarian and breast cancer regardless of family history.
- Internal data on file at Myriad Genetics, Inc.